Yes, Trelegy Ellipta is FDA-approved for asthma. It received its asthma indication in September 2020, several years after its original 2017 approval for COPD. It’s approved specifically as a maintenance treatment for adults 18 and older whose asthma isn’t adequately controlled on their current regimen. This isn’t a first-line inhaler. It’s designed for people who are already using a two-drug inhaler and still having symptoms.
What Trelegy Actually Does
Trelegy combines three medications into a single inhaler, each targeting a different aspect of airway problems. The first is an inhaled corticosteroid that reduces inflammation in the airways, calming the immune response that causes swelling and mucus production. The second is a long-acting bronchodilator that relaxes the smooth muscle around your airways by stimulating receptors that keep those muscles from tightening. The third is an anticholinergic, which opens the airways through a completely different pathway: it blocks signals from the nervous system that tell airway muscles to constrict.
This three-pronged approach is sometimes called “triple therapy.” Most people with moderate to severe asthma start on a two-drug inhaler (a steroid plus one bronchodilator). Trelegy adds that third mechanism when two drugs aren’t enough.
Who It’s Meant For
Trelegy sits near the top of the asthma treatment ladder. Asthma guidelines recommend stepping up treatment gradually. You’d typically start with an inhaled steroid alone, then move to a steroid plus a long-acting bronchodilator. If that combination still leaves you with persistent symptoms, flare-ups, or nighttime waking, triple therapy with an added anticholinergic becomes an option. Biologic injections are the other major addition considered at this stage.
In practical terms, Trelegy is most appropriate if you’re already using a two-drug maintenance inhaler daily and still reaching for your rescue inhaler multiple times a week, waking up at night with symptoms, or experiencing exacerbations that require oral steroids. It is not for mild or intermittent asthma, and it’s only approved for adults.
How Well It Works
The key clinical trial for Trelegy in asthma, known as the CAPTAIN study, tested whether adding the anticholinergic component to a standard steroid/bronchodilator inhaler made a meaningful difference. It did, at least for lung function. Patients on Trelegy saw their lung capacity improve by about 92 to 110 milliliters more than patients on the two-drug inhaler alone. That’s a statistically significant and clinically noticeable difference in how much air you can force out in one second.
The picture on flare-ups was less clear. The CAPTAIN trial found reductions in moderate and severe exacerbations, but those reductions weren’t large enough to be statistically significant. So Trelegy reliably opens your airways more than a two-drug inhaler, but the evidence that it prevents asthma attacks is not as strong. Higher steroid doses within the inhaler did seem to lower exacerbation rates more than the addition of the third drug.
Dosing and How You Take It
Trelegy comes in a dry powder inhaler called the Ellipta. You take one inhalation once a day, at the same time each day. There are two strengths available for asthma: one with 100 micrograms of the steroid component and another with 200 micrograms. The other two ingredients stay the same in both versions (62.5 mcg of the anticholinergic and 25 mcg of the bronchodilator). Your prescriber picks the steroid strength based on how severe your asthma is.
One critical point: Trelegy is a maintenance inhaler only. It does not work as a rescue inhaler. It won’t relieve an asthma attack in progress. You still need a separate fast-acting rescue inhaler for sudden symptoms.
What Trelegy Won’t Replace
Because Trelegy is a once-daily controller, it works by keeping your airways calm and open over time. It takes consistent daily use to build its full effect. If you’re having an acute episode with chest tightness or wheezing, Trelegy won’t help in the moment. You should always have a short-acting rescue inhaler available.
Trelegy also isn’t a substitute for a treatment plan adjustment if your asthma is worsening rapidly. A sudden increase in symptoms, especially needing your rescue inhaler more than usual, warrants a conversation with your prescriber rather than simply adding Trelegy on your own.
Side Effects to Expect
The side effects of Trelegy reflect its three components. The inhaled steroid can cause oral thrush (a yeast infection in the mouth) and hoarseness. Rinsing your mouth after each use reduces this risk significantly. The anticholinergic component can cause dry mouth, constipation, and urinary retention, particularly in men with prostate issues. The bronchodilator can cause headaches, a slightly elevated heart rate, and muscle cramps.
Because the inhaler contains a milk-derived protein (lactose), people with a severe milk protein allergy may need to avoid it. This is different from lactose intolerance, which typically isn’t a concern.
Long-term inhaled steroid use at higher doses carries risks that apply to any steroid-containing inhaler: reduced bone density, increased eye pressure, and a small increase in pneumonia risk. These risks are generally low at the doses used in asthma inhalers but become more relevant the longer you use them.
How Trelegy Compares to Using Separate Inhalers
Before Trelegy existed, people who needed triple therapy had to use two or even three separate inhalers to get the same combination of medications. The main advantage of Trelegy is simplicity: one device, one puff, once a day. Studies across respiratory medicine consistently show that people are more likely to use their inhalers correctly and consistently when the regimen is simpler. For a condition like asthma, where skipping doses leads directly to worsening symptoms, that convenience has real clinical value.
The trade-off is flexibility. With separate inhalers, your prescriber can adjust each medication independently. With Trelegy, the only variable is the steroid dose (100 or 200 mcg). If you need a change to just one component, you may need to switch back to individual inhalers.